Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY3962673 · 1 trial · 3 indications
A summary of TEAEs, SAEs and other non-serious adverse events (AEs), regardless of causality, will be reported in the Reported Adverse Events module.
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)
BOR per investigator assessed RECIST 1.1
DOR per investigator assessed RECIST 1.1
TTR per investigator assessed RECIST 1.1
DCR per investigator assessed RECIST 1.1
| Arm | Type | Description |
|---|---|---|
| Phase 1a: LY3962673 Dose Escalation | EXPERIMENTAL | Escalating doses of LY3962673 administered orally. |
| Phase 1b: LY3962673 Dose Expansion | EXPERIMENTAL | LY3962673 administered orally either alone or in combination with other chemotherapy agents. |
| Experimental: Phase 1a: LY3962673 Monotherapy | EXPERIMENTAL | LY3962673 administered orally |
| Name | Type | Description |
|---|---|---|
| LY3962673 | DRUG | Administered orally. |
| Cetuximab | DRUG | Administered intravenously. |
| Gemcitabine | DRUG | Administered intravenously. |
| nab-paclitaxel | DRUG | Administered intravenously. |
| Oxaliplatin | DRUG | Administered intravenously. |
| leucovorin | DRUG | Administered intravenously. |
| Irinotecan | DRUG | Administered intravenously. |
| 5-fluorouracil | DRUG | Administered intravenously. |
Inclusion Criteria: * Have Histological or cytologically proven diagnosis of locally advanced, unresectable, and/or metastatic cancer and measurable disease per Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. * Have evidence of KRAS G12D mutation in tumor tissue or circulating tu...
LY3962673 is an investigational small molecule being studied for the treatment of Pancreatic Ductal Adenocarcinoma. It is also being evaluated in Non-small Cell Lung Cancer and Colorectal Cancer. The drug is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
LY3962673 targets KRAS G12D, a specific mutation in the KRAS gene. This mutation is associated with certain solid tumors, including Pancreatic Ductal Adenocarcinoma. By targeting KRAS G12D, the drug aims to interfere with cancer cell growth driven by this genetic alteration.
LY3962673 is being developed by Eli Lilly and Company, a pharmaceutical company traded on the stock exchange under the ticker symbol LLY. The drug is currently in Phase 1 clinical trials for the treatment of KRAS G12D-mutant solid tumors.
LY3962673 is in Phase 1 clinical development. It is an investigational drug, meaning it has not yet been approved by regulatory agencies. The ongoing Phase 1 trial is recruiting participants to evaluate the drug's safety and efficacy in patients with KRAS G12D-mutant solid tumors.
LY3962673 is being studied in the MOONRAY-01 trial, identified as NCT06586515. This Phase 1 study is recruiting participants with KRAS G12D-mutant solid tumors, including Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, and Colorectal Cancer. The trial is enrolling approximately 630 participants across multiple countries.
LY3962673 is the drug being studied in the MOONRAY-01 trial. MOONRAY-01 is the name of the clinical study, while LY3962673 is the investigational drug. The trial is designed to evaluate the drug in participants with KRAS G12D-mutant solid tumors.